RxDoctor Payments Data

Hossein Sadeghi-Nejad, MD

Urology · East Orange, NJNPI 1336118850

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Verity Pharmaceuticals Inc. at 42.7% of the total. 2025 is the largest year on record at $16,196, more than ten times the $130 reported in 2022. Among urology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,100in general payments, 2019–2025

Across 40 payments — averaging $452.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verity Pharmaceuticals Inc.$8K
  • Endo USA, Inc.$7K
  • Novo Nordisk$2K
  • Boston Scientific$288
  • Profound Medical Corp.$206
  • Coloplast$199
  • plus $733 from 8 others

What the payments were for

  • Consulting fees$7,95544%
  • Speaking & faculty fees$7,00039%
  • Travel & lodging$1,6069%
  • Food & beverage$1,5409%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,100 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$73,438
Medicare patients
199
Services billed
1,398

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyostedTestosterone Enanthate65$39,310
MyrbetriqMirabegron23$16,899
Tamsulosin Hcl100$2,121
Tadalafil21$2,035
Alfuzosin Hcl ErAlfuzosin Hcl83$1,792
Finasteride136$1,535
Anastrozole11$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Antares Pharma, Inc.Xyosted$71$39,31065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.

Other urology in East Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →